Solvent/detergent treatment claims appear within a broader set of 66 records that also cover nanofiltration, prion removal and viral clearance validation methods. Most of these records also carry a C07K peptide/protein classification, meaning solvent/detergent claims are frequently bundled with downstream purification steps rather than filed as a standalone method. A freedom-to-operate check should look at the leading assignee's portfolio first, since it holds 28 of the ranked records, well ahead of the rest of the field.

The assignee ranking covers 13 companies, with the leader holding 28 records against a fifth-place count of only 3 and a tenth-place count of 2. That is a steep drop-off, meaning the field has one clearly dominant filer and a long tail of much smaller holders. Recent-year momentum data shows zero new filings from any of the named leaders in the latest year, so current activity should be checked directly against filing dates rather than assumed from historical rank.

Filing activity peaked at 16 records in 2017 and has declined since, with the 2026 count showing 0 filings as of the data cut-off. Because publication typically lags actual filing by around 18 months, the last one to two years are understated and should not be read as a true drop to zero. Even accounting for that lag, the multi-year trend from the 2017 peak points to a genuine slowdown rather than a data artefact alone.

C07K (peptides and proteins) is the most common classification, appearing on 69.7% of the 66 records in scope, followed by C12N (microorganisms and genetic engineering) at 36.4% and B01D (separation processes such as filtration) at 30.3%. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be read as mutually exclusive categories. Smaller classes like B01F (mixing) and G01N (material analysis) each appear on only 1.5% of records, marking them as comparatively open areas.

The densest claim space sits in C07K-classified purification methods, which touch 69.7% of records, so a new filing purely in that space will face heavy prior art. Thinner areas include fluorescent viral surrogate validation methods, prion-specific removal claims, and the B01F mixing/stirring and C12Q enzyme-testing subclasses, each appearing on 13.6% or less of records. A first claim in one of these adjacent branches, tied to a specific validation method rather than the inactivation step itself, is more likely to clear prior art cleanly.